Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUNAVAIL vs BUPRENEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
FDA-approved for the treatment of opioid dependence, including induction and maintenance therapy.
Treatment of opioid dependence,Management of moderate to severe pain (off-label)
For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
Terminal elimination half-life of buprenorphine is approximately 24-42 hours (mean ~37 hours) due to slow dissociation from mu-opioid receptors, supporting extended dosing intervals.
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
Buprenorphine is primarily metabolized via N-dealkylation by CYP3A4 to norbuprenorphine; also undergoes glucuronidation. Naloxone undergoes hepatic metabolism primarily by glucuronidation.
Primarily N-dealkylation via CYP3A4; also conjugation by UGT enzymes (UGT1A1, UGT2B7).
Fecal (~70%) as unconjugated buprenorphine and metabolites; renal (~30%) primarily as conjugated metabolites.
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
Approximately 96% bound to alpha- and beta-globulins, not significantly to albumin.
96% bound to alpha- and beta-globulins, and albumin.
Vd: 2.5-4.0 L/kg, indicating extensive tissue distribution and high lipophilicity.
Volume of distribution is 430-600 L (approximately 2.8 L/kg), indicating extensive tissue distribution.
Buccal: ~30-40% relative to intravenous; sublingual: ~30% due to first-pass metabolism; buccal route avoids some gastrointestinal degradation.
Sublingual: 30-50% (due to first-pass metabolism); buccal: 50-60%; oral: 15-30% (not clinically used); intravenous: 100%.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl < 30 m L/min): use with caution; consider dose reduction or extended intervals due to potential accumulation of buprenorphine.
No specific dose adjustment required for GFR >30 m L/min; for GFR 15-30 m L/min, consider cautious dosing and extended intervals; for GFR <15 m L/min, use with caution and consider dose reduction.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B): reduce starting dose by 50% and titrate slowly. For mild impairment (Child-Pugh class A): no dose adjustment required.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use or reduce dose by 75%.
Not approved for patients under 16 years; safety and efficacy not established. For adolescents 16 years and older: use adult dosing based on weight and severity.
Not recommended for children under 2 years; for age 2-12 years: 2-6 mcg/kg intramuscularly or intravenously every 4-6 hours; maximum single dose 0.3 mg.
No specific dose adjustment in elderly; use caution due to increased sensitivity, impaired hepatic/renal function, and risk of falls. Start at low end of dosing range and titrate slowly.
Start with 0.15 mg intramuscularly or intravenously every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Risk of addiction, abuse, and misuse; respiratory depression and death with IV administration; neonatal opioid withdrawal syndrome with prolonged use; risk of opioid withdrawal with abrupt discontinuation; risk of hepatitis, hepatic events; precipitation of withdrawal if given to patients dependent on full agonists.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of death with intravenous administration; risk of serious adverse events when used with benzodiazepines or other CNS depressants.
Respiratory depression; neonatal opioid withdrawal syndrome; hepatic injury; precipitation of opioid withdrawal; risks from concomitant use with benzodiazepines or CNS depressants; dependence and withdrawal; use in patients with compromised respiratory function; increased intracranial pressure; hypotension; biliary tract disease; QT prolongation; impairment of driving/operating machinery.
Respiratory depression; CNS depression; risk of dependence and abuse; adrenal insufficiency; QT prolongation; severe injection site reactions; risk of precipitating withdrawal in opioid-dependent patients; neonatal withdrawal syndrome; impairment of ability to drive or operate machinery.
Hypersensitivity to buprenorphine or naloxone; patients with significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; patients not already dependent on opioids (for induction).
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe asthma; GI obstruction; elevated CSF pressure; use of MAOIs within 14 days.
No significant food interactions. However, patients should avoid grapefruit juice as it may increase buprenorphine levels. Advise to take on an empty stomach for consistent absorption, though food does not significantly alter bioavailability.
No specific food interactions are reported. Grapefruit juice has not been shown to significantly alter buprenorphine metabolism. Advise patients to maintain a balanced diet to manage opioid-induced constipation.
Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Use in pregnancy only if benefit outweighs risk.
Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) and neonatal respiratory depression. Risk of preterm labor and low birth weight. Use only if benefit outweighs risk.
Buprenorphine is excreted into breast milk in low concentrations; estimated relative infant dose is 2.4% of maternal weight-adjusted dose. M/P ratio is not well established. Caution is advised, monitor for infant sedation and respiratory depression.
Buprenorphine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.9. Limited data suggest no adverse effects in breastfed infants at maternal doses up to 24 mg/day. However, monitor infant for sedation and respiratory depression. Benefits of breastfeeding outweigh risks in opioid-dependent mothers on maintenance therapy.
Pregnancy may alter buprenorphine pharmacokinetics; dose adjustments may be needed to avoid withdrawal or oversedation. Monitor clinical response and adjust doses in increments of 2-4 mg sublingual buprenorphine as needed, guided by withdrawal symptoms and cravings.
No specific dose adjustments are recommended for buprenorphine during pregnancy. However, due to increased plasma volume and hepatic clearance, some patients may require dose increases in the second and third trimesters to avoid withdrawal symptoms. Close monitoring of therapeutic response and withdrawal signs is advised.
BUNAVAIL (buprenorphine/naloxone) sublingual film is indicated for maintenance treatment of opioid dependence. Administer as a single daily dose; films can be cut to achieve lower doses. Avoid abrupt discontinuation to prevent withdrawal. Monitor for respiratory depression, especially during induction. Use with caution in patients with hepatic impairment; naloxone component may precipitate withdrawal in opioid-tolerant patients if injected.
Buprenorphine (Buprenex) is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu-receptors, which can precipitate withdrawal if given to opioid-dependent patients. Monitor for respiratory depression, especially in combination with CNS depressants. Use with caution in hepatic impairment; adjust dose in moderate to severe impairment.
Place the film under the tongue and allow it to dissolve completely; do not chew, swallow, or move the film after placement.,Do not drink or eat until the film has completely dissolved.,Avoid use of alcohol or other central nervous system depressants (e.g., benzodiazepines) while taking this medication as it may increase risk of respiratory depression.,Do not stop taking this medication suddenly without consulting your healthcare provider as withdrawal symptoms may occur.,Store at room temperature away from moisture and heat; keep out of reach of children.,This medication can cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.,Inform all healthcare providers that you are taking this medication before any surgery or emergency treatment.,Do not take other opioids, including illicit drugs, while on this medication as it may cause severe withdrawal or overdose.
Do not stop taking this medication abruptly as it may cause withdrawal symptoms; follow your doctor's instructions for tapering.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness or respiratory depression.,This medication can cause constipation; increase fluid and fiber intake, and consider stool softeners.,Store securely away from children and pets, as accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUNAVAIL vs BUPRENEX, answered by our medical review team.
BUNAVAIL is a Opioid Partial Agonist Combination that works by Buprenorphine is a partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist; naloxone is a mu-opioid receptor antagonist that prevents misuse via injection.. BUPRENEX is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUNAVAIL and BUPRENEX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUNAVAIL is: For moderate to severe opioid use disorder: sublingual film, induction: 2-4 mg buprenorphine/0.5-1 mg naloxone on day 1, then up to 8 mg/2 mg on day 2; maintenance: target 16 mg/4 mg sublingually once daily, range 4-24 mg/1-6 mg daily.. The standard adult dose of BUPRENEX is: 0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUNAVAIL and BUPRENEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUNAVAIL is classified as Category C. Buprenorphine, a component of BUNAVAIL, is not associated with major congenital malformations. However, third-trimester use may cause neonatal opioid withdrawal syndrome (NOWS) and. BUPRENEX is classified as Category C. Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high dos. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.